Activation of CD44 facilitates DNA repair in T-cell lymphoma but has differential effects on apoptosis induced by chemotherapeutic agents and ionizing radiation

References

• Naor D, Sionov R V, Ish-Shalon D. CD44: structure, function and association with malignant process. Advanced Cancer Research 1997; 72: 241–319
   Web of Science ®Google Scholar
• Haynes B F, Telen M J, Hale L P, Denning S M. CD44-A molecule involved in leukocytes adherence and T-cell activation. Immunology Today 1989; 10: 423–428
   PubMedGoogle Scholar
• Galandrini R, Albi N, Tripodi G, Zarcone D, Terenzi A, Moretta A. Antibodies to CD44 trigger effect or functions of human T cell clones. Journal of Immunology 1993; 150: 4225–4235
   PubMed Web of Science ®Google Scholar
• Salles G, Zain M, Jiang W M, Boussiotis V A, Shipp M A. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993; 82: 3539–3547
   PubMed Web of Science ®Google Scholar
• Ristamaki R, Joensuu H, Soderstom K O, Jalkanen S. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis. Journal of Pathology 1995; 176: 259–267
   PubMed Web of Science ®Google Scholar
• Pals S T, Horst E, Ossekoppele G J, Figdor C C, Scheper R J, Meijer C J. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 1989; 73: 885–888
   PubMed Web of Science ®Google Scholar
• Jalkanen S, Joensuu H, Klemi P. Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma. Blood 1990; 75: 1549–1556
   PubMed Web of Science ®Google Scholar
• Sy M S, Guo Y J, Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. Journal of Experiment Medicine 1991; 174: 859–866
   PubMed Web of Science ®Google Scholar
• Wang Y, Rea T, Bian J, Gray S, Sun Y. Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology. FEBS Journal 1999; 445: 269–273
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Gobl A, Eriksson B, Skogseid B, Oberg K. Different splice variants of CD44 are expressed in gastrinoma but not in other subtypes of endocrine pancreatic tumors. Cancer Research 1994; 54: 981–986
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, Jackson D, Bennelt K, Aruffo A, Dickison R, Shields J, et al. Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. Journal of Cell Science 1995; 108: 1723–1733
   PubMed Web of Science ®Google Scholar
• Driessens M HE, Stroeken P JM, Erena N F, van der Valk M A, van Rijithoven E AM, Roos E. Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity. Journal of Cell Biology 1995; 131: 1849–1855
   PubMed Web of Science ®Google Scholar
• Ayroldi E, Cannarile L, Migliorati G, Bartoli A, Nicoletti I, Riccadi C. CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood 1995; 86: 2672–2678
   PubMed Web of Science ®Google Scholar
• Guy R, Yefenof E, Naor D, Dorogin A, Ziolberman Y. CD44 co-stimulates apoptosis in thymic lymphomas and T cell hybridomas. Cellular Immunology 2002; 216: 82–92
   PubMed Web of Science ®Google Scholar
• Liu K, Kasper M, Bierhaus A, Langer S, Peterson I, Muller M. Differential expression of CD44s and CD44v10 proteins and sydeean in normal and irradiated mouse epidermis. Histochemistry and Cell Biology 1997; 107: 159–167
   PubMed Web of Science ®Google Scholar
• Wu Z, Chen C L, Eastman S, Bresnick E. Expression of human O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compound. Molecular Carcinogenesis 1991; 4: 482–488
   PubMed Web of Science ®Google Scholar
• Dabholkar M, Vionnet J, Bostick-Bruton F, Yu J J, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. Journal of Clinical Investigation 1994; 94: 703–708
   PubMed Web of Science ®Google Scholar
• Koberle B, Master J RW, Hartley J A, Wood R D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumors. Current Biology 1999; 9: 273–276
   PubMed Web of Science ®Google Scholar
• Kartalou M, Essigmann J M. Mechanism of resistance to cisplatin. Mutation Research 2001; 478: 23–43
   PubMed Web of Science ®Google Scholar
• Lai G M, Ozols R F, Smyth J F, Young R C, Hamilton T C. Enhanced DNA repair and resistance to cisplatin in human cancer. Biochemical Pharmacology 1988; 37: 4597–4600
   PubMed Web of Science ®Google Scholar
• Selden J R, Dolbeare F, Clair J H, Nichols W W, Miller J E, Kleemeyer K M. Statistical confirmation that immunofluorescent detection of DNA repair in human fibroblasts by incorporation is stoichiometric and sensitive. Cytometry 1993; 14: 154–167
   PubMedGoogle Scholar
• Lesley J, Schulte R, Hyman R. Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1. Experiment Cell Research 1990; 187: 224–233
   PubMed Web of Science ®Google Scholar
• Li R, Walker J R, Johnson P. Chimeric CD4/CD44 molecules associated with CD44 via the transmembrane region and reduce hyaluronan binding in T cell lines. European Journal of Immunology 1998; 28: 1745–1754
   PubMed Web of Science ®Google Scholar
• Fujita Y, Kitagawa M, Nakamura S, Azuma K, Ishii G, Higashi M. CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Letters 2002; 528: 101–108
   PubMed Web of Science ®Google Scholar
• Okamoto I, Kawano Y, Murakami D, Saayama T, Araki N, Miki T, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. Journal of Cell Biology 2001; 155: 755–762
   PubMed Web of Science ®Google Scholar
• Shi M, Dennis K, Peschon J J, Chandrasekaran R, Mikecz K. Antibody-induced shedding of CD44 from adherent cells is linked to the assembly of the cytoskeleton. Journal of Immunology 2001; 167: 123–131
   PubMed Web of Science ®Google Scholar
• Schein P S, DeVita V T, Jr, Hubbard S, Young R C. Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisolone (BACOP) combination chemotherapy in the treatment of advance diffuse histiocytic lymphoma. Annals of Internal Medicine 1976; 85: 417–422
   PubMed Web of Science ®Google Scholar
• Haimoritz-Friedman A, Kan C C, Ehleiter D, Persand R S, McLoughlin M, Fuks Z. Ionizing radiation acts on cellular membrane to generate uramide and initiate apoptosis. Journal of Experiment Medicine 1994; 180: 525–535
   PubMed Web of Science ®Google Scholar
• Huschtscha L I, Bartier W A, Ross C EA, Talttersall M HN. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. British Journal of Cancer 1996; 73: 54–60
   PubMed Web of Science ®Google Scholar
• Waga S, Hannon G J, Beach O, Stillman B. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 1994; 369: 574–578
   PubMed Web of Science ®Google Scholar
• Rudolph P, Tronnier M, Menzel R, Moller M, Parwaresch R. Enhanced expression of Ki-67, topoisomerase II α, PCNA, p53 and p21WAF/Cip1 reflecting proliferation and repair activity in UV-irradiated melanocytic nevi. Human Pathology 1998; 29: 1480–1487
   PubMed Web of Science ®Google Scholar
• Friedberg E C. How nucleotide excision repair protects against cancer. Nature Review of Cancer 2001; 1: 22–33
   PubMed Web of Science ®Google Scholar
• Murray D, Vallee-Lucic L, Rosenberg E, Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Research 2002; 22: 21–26
   PubMed Web of Science ®Google Scholar
• Rothman B L, Blue M L, Kelley K A, Wunderlich D, Mierz D V, Aune T M. Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44. Journal of Immunology 1991; 147: 2493–2499
   PubMed Web of Science ®Google Scholar
• Guo Y J, Lin S C, Wang J H, Bigby M, Sy M S. Palmitoylation of CD44 interferes with CD3-mediated signaling in human T lymphomcytes. International Immunology 1994; 6: 213–221
   PubMed Web of Science ®Google Scholar
• Sugiyama K, Komada Y, Deguchi T, Zhang X L, Azuma E, Ido M. CD3-mediated T cell activation is inhibited by anti-CD44 monoclonal antibodies directed to the hyaluronan-binding region. Immunology Investigation 1999; 28: 185–200
   PubMed Web of Science ®Google Scholar
• Lei H Y, Tang M T, Tsao N. Intracellular alkalinization in dexamethasone-induced thymocyte apoptosis. Apoptosis 1997; 2: 304–312
   PubMed Web of Science ®Google Scholar
• Tong D C, Buck S M, Roberts B R, Klein J D, Tumin J A. Calcineurin phosphatase activity: activation by glucocorticoids and role of intracellular calcium. Transplanation 2004; 77: 259–267
   PubMed Web of Science ®Google Scholar
• Tonko M, Ausserlechner M J, Bernhard D, Helmberg A, Kofler R. Gene expression profiles of proliferating vs G1/G0 arrest human leukemia cells suggest a mechanism of glucocorticoid-induced apoptosis. FASEB Journal 2001; 15: 693–699
   PubMed Web of Science ®Google Scholar
• Wiman K G, Magnusson K P, Ramqvist T, Klein G. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 1991; 6: 1633–1639
   PubMed Web of Science ®Google Scholar
• Sangfelt O, Erickson S, Einhorn S, Grander D. Induction of Cip/Kip and Ink 4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 1997; 14: 415–423
   PubMed Web of Science ®Google Scholar
• Dunkern T R, Wedemeyer I, Baumgartner M, Fritz G, Kaina B. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair 2003; 2: 49–60
   PubMed Web of Science ®Google Scholar